India Glycols Limited has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a total income of ₹2,987.30 crore and a profit after tax of ₹76.59 crore (standalone). The consolidated results also showed a profit after tax of ₹96.83 crore for the same period. The Board of Directors has approved these results, which reflect the company’s performance in the initial quarter of the fiscal year.
India Glycols Reports Q1 FY27 Unaudited Financial Results
India Glycols Limited has officially announced its unaudited financial results for the first quarter, which concluded on June 30, 2026. The Board of Directors, in a meeting held on August 12, 2026, considered and approved these results, encompassing both standalone and consolidated figures.
Standalone Financial Performance
For the standalone operations, India Glycols reported a total income of ₹2,987.30 crore for the quarter ended June 30, 2026. This figure is a combination of revenue from operations amounting to ₹2,986.92 crore and other income of ₹0.38 crore. The company posted a profit after tax of ₹76.59 crore, with total comprehensive income standing at ₹76.40 crore for the period. The profit before tax was ₹102.64 crore.
Consolidated Financial Performance
On a consolidated basis, which includes its subsidiaries and joint ventures, India Glycols reported a total income of ₹2,988.82 crore. The revenue from operations contributed ₹2,988.44 crore to this total. The consolidated profit after tax for the first quarter of FY27 was ₹96.83 crore, with total comprehensive income recorded at ₹96.68 crore. The consolidated profit before tax was also ₹102.64 crore.
Key Financial Metrics
The financial results highlight key operational figures. Total expenses for standalone operations were ₹2,884.66 crore, leading to a profit before interest, depreciation, and tax (EBITDA) of ₹170.30 crore. For consolidated operations, total expenses stood at ₹2,886.54 crore, with a consolidated EBITDA of ₹169.94 crore.
Segment-wise Performance (Standalone)
The company’s segment revenue report for the quarter ended June 30, 2026, shows significant contributions from different divisions. The Bio-based Specialities and Performance Chemicals segment generated revenue of ₹361.73 crore, while the largest segment, Potable Spirits, reported revenue of ₹2,218.67 crore. Ennature Biopharma contributed ₹83.30 crore, and the Bio-Fuel segment added ₹323.22 crore. Segment results (Profit/(Loss) before interest and tax) indicate positive contributions across all segments, with Potable Spirits leading at ₹75.03 crore.
Other Comprehensive Income
The statement also details other comprehensive income. For standalone operations, there was a net decrease of ₹0.19 crore in other comprehensive income. Consolidated other comprehensive income also showed a net decrease of ₹0.15 crore.
Board Meeting Details
The Board Meeting commenced at 15:45 Hrs. and concluded at 16:50 Hrs. on August 12, 2026. The company also referenced a previous letter dated August 5, 2026, regarding this upcoming board meeting.
Auditor’s Review
The unaudited financial results have undergone a limited review by the Statutory Auditors and the Audit Committee. The auditors’ report confirms that based on their review, nothing has come to their attention that causes them to believe the accompanying statement contains any material misstatement.
Source: BSE
